Bonstein Sara 4

What Happened Sara Bonstein, a director of Xilio Therapeutics, was granted a derivative award on June 11, 2026 covering 5,000 shares. The Form 4 reports the transaction as an award/grant (code A) at $0.00, indicating no cash purchase; this is an option-style grant rather than an open-market trade.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (timely filing).
• Grant: 5,000-share option award reported at $0.00 (derivative).
• Vesting: The option vests 100% on the earlier of (i) June 11, 2027 or (ii) the issuer's next annual meeting of stockholders, subject to continued service. (Footnote from filing.)
• Shares owned after transaction: Not specified in the supplied filing details.
• No indication of a 10b5-1 plan, cashless exercise, tax withholding, or late filing in the provided information.

Context This filing documents a common form of director compensation (an option grant) rather than a market purchase or sale. The $0.00 reporting reflects that it is an award/option grant; exercise price and any future sales would be reported in subsequent filings if executed.